Search results
Showing 1156 to 1170 of 8244 results
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.
View recommendations for TA380Show all sections
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.
View recommendations for TA373Show all sections
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults.
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Cabozantinib for untreated advanced renal cell carcinoma (TA542)
Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults.
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)
Evidence-based recommendations on gemtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia in people aged 15 years and over.
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)
Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.
Show all sections